BMRNHealthcare · BiotechnologyThe 27 Wall Street analysts covering BioMarin Pharmaceutical, Inc. hold a median 12-month price target of $90 — +60.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 5 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores BioMarin Pharmaceutical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (22): The company has been issuing shares or taking on financing, diluting existing holders.
Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BMRN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +60.1% from it.
Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Sept 2026 | HC Wainwright & Co. | Reiterates | Neutral | $60 |
| 1 Sept 2026 | Piper Sandler | Maintains | Overweight | $88 → $90 |
| 1 Sept 2026 | Piper Sandler | Maintains | Overweight | — |
| 31 Aug 2026 | HC Wainwright & Co. | Maintains | Neutral | — |
| 31 Aug 2026 | HC Wainwright & Co. | Maintains | Neutral | $59 → $60 |
| 31 Aug 2026 | Jefferies | Maintains | Buy | — |
| 31 Aug 2026 | Jefferies | Maintains | Buy | $104 → $105 |
| 19 Aug 2026 | BMO Capital | Initiates | Outperform | $98 |
| 19 Aug 2026 | BMO Capital | Initiates | Outperform | — |
| 18 Aug 2026 | HC Wainwright & Co. | Maintains | Neutral | $60 → $59 |
| 18 Aug 2026 | HC Wainwright & Co. | Maintains | Neutral | — |
| 17 Aug 2026 | Barclays | Maintains | Overweight | — |
| 17 Aug 2026 | Barclays | Maintains | Overweight | $105 → $111 |
| 17 Aug 2026 | Piper Sandler | Maintains | Overweight | $82 → $88 |
| 17 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
| 10 Aug 2026 | Canaccord Genuity | Maintains | Buy | — |
| 10 Aug 2026 | Canaccord Genuity | Maintains | Buy | $111 → $114 |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Neutral | $50 → $60 |
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Neutral | — |
| 7 Aug 2026 | Morgan Stanley | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BMRN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 6 Oct 2026, BioMarin Pharmaceutical, Inc. returned +1.1% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 5% of US stocks
Cheaper than 37% of US stocks
Cheaper than 49% of US stocks
Cheaper than 13% of US stocks
Higher than 69% of US stocks
Higher than 5% of US stocks
Higher than 90% of US stocks
Higher than 80% of US stocks
Higher than 52% of US stocks
Higher than 46% of US stocks
Higher than 67% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
BioMarin Pharmaceutical, Inc. has a market value of $11.1B and an enterprise value of $14.4B.
Revenue in the twelve months to 30 June 2026: $3.4B. The latest quarter grew 19.9% year on year.
Net income over the same four quarters: $73.0M, a 2.1% net margin.
Diluted earnings per share, trailing twelve months: $0.37.
Free cash flow in the twelve months to 30 June 2026: $725.1M.
Trailing P/E: 154.5×; forward P/E: 8.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
BioMarin Pharmaceutical, Inc. employs 3,221 people — $1.1M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own BioMarin Pharmaceutical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
BioMarin Pharmaceutical announced that Cara Bauer, Ph.D., will join as Chief People Officer, effective Oct. 5, 2026. Bauer brings more than 25 years of human resources experience across biotechnology and technology industries.
Why it matters — A seasoned HR leader joining the executive team signals continuity in people leadership as BioMarin continues to operate across the biotechnology sector.
BioMarin reported five-year data from its combination therapy for adults with late-onset Pompe disease showing durable maintenance of walking distance and relatively stable respiratory function, with no new safety signals identified.
Why it matters — The long-term efficacy and safety data provide further clinical evidence supporting BioMarin's Pompe disease program in a sustained treatment setting.
BioMarin presented five-year Phase 3 data at the 31st Annual Congress of the World Muscle Society in Hiroshima, Japan, reporting durable efficacy and safety for POMBILITI (cipaglucosidase alfa-atga) plus OPFOLDA (miglustat) in late-onset Pompe disease.
Why it matters — Long-term Phase 3 data reinforcing the durability of the POMBILITI + OPFOLDA therapy matters to BioMarin watchers as it supports the product's efficacy and safety profile in the late-onset Pompe disease market.
Profluent announced a collaboration with BioMarin Pharmaceutical to apply its AI foundation models to design and optimize novel enzyme therapies for BioMarin's pipeline. BioMarin will screen the generated drug candidates with the goal of advancing the most promising designs.
Why it matters — This partnership could bring advanced AI-driven approaches to BioMarin's drug development pipeline, potentially strengthening its enzyme therapy efforts in a complex area.
BioMarin raised its full-year 2026 revenue guidance from $3.83-$3.93 billion to $3.88-$3.93 billion. The company anticipates multiple catalysts into late 2026 and 2027, including 12 mg/kg BMN 351 Phase 1/2 data in Duchenne muscular dystrophy by year-end 2026 and a potential H1 2027 approval of Voxzogo for hypochondroplasia.
Why it matters — Investors may be interested in these upcoming clinical and regulatory catalysts and the company's improved revenue outlook heading into 2026-2027.
The 27 Wall Street analysts covering BioMarin Pharmaceutical, Inc. have a median 12-month price target of $90, with estimates ranging from $60 to $124. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 27 analysts covering BioMarin Pharmaceutical, Inc., 20 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioMarin Pharmaceutical, Inc. 61 out of 100 across roughly 4,600 US stocks as at 5 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 5 Oct 2026, BioMarin Pharmaceutical, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 27 analysts implies +60.1% from the last close, and Ticker Nerd's factor model ranks BioMarin Pharmaceutical, Inc. 61 out of 100 as at 5 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering BioMarin Pharmaceutical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMRN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $60 to $124 over the next 12 months.
BioMarin Pharmaceutical, Inc. returned +1.1% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
BioMarin Pharmaceutical Inc. is a global biotechnology company focused on developing and commercializing therapies for rare genetic and metabolic diseases.
The most recent item we track (PRNewsWire, 5 Oct 2026): "BioMarin Appoints Cara Bauer as Chief People Officer". BioMarin Pharmaceutical announced that Cara Bauer, Ph.D., will join as Chief People Officer, effective Oct. 5, 2026. Bauer brings more than 25 years of human resources experience across biotechnology and technology industries.
BioMarin Pharmaceutical Inc. is a global biotechnology company focused on developing and commercializing therapies for rare genetic and metabolic diseases. Its portfolio includes approved medicines and advanced treatments such as enzyme replacement therapies, gene therapies, and other specialized biologics designed for patients living with genetically defined conditions. BioMarin’s products are used in areas including lysosomal storage disorders, achondroplasia, hemophilia, phenylketonuria, and other serious rare diseases. The company serves a specialized role in the healthcare market by addressing conditions that often have limited treatment options, with a business model centered on research, regulatory development, manufacturing, and global commercialization of orphan-disease therapies. Headquartered in San Rafael, California, BioMarin Pharmaceutical Inc. is recognized as a leading rare disease biotechnology company.
CEO Mr. Alexander Hardy · 3,221 employees · United States · https://www.biomarin.com
